ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO1154

Real-World Effectiveness of Finerenone in Chinese CKD Patients Without Type 2 Diabetes

Session Information

  • Late-Breaking Posters
    November 02, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: CKD (Non-Dialysis)

  • 2303 CKD (Non-Dialysis): Mechanisms


  • Zhou, Li, China-Japan Friendship Hospital, Beijing, Beijing, China
  • Li, Wenge, China-Japan Friendship Hospital, Beijing, Beijing, China

No evidence has been reported for using finerenone in non-diabetic chronic kidney disease (CKD), although it is proven effective and safe for patients with CKD and type 2 diabetes(T2D).


This real-world retrospective study included Chinese CKD patients without T2D between November 2022 and August 2023. Patients received standard CKD treatment plus finerenone at dose of 10 or 20 mg once daily. Urinary albumin to creatinine ratio (UACR), estimated glomerular filtration rate (eGFR), and serum potassium (sK+) were examined at baseline, 1 month, and 3 months after treatment.


Totally 16 patients were analyzed (mean age: 55.38±14.37 years; 12 [75.0%] males) (Table 1). UACR was remarkably reduced compared to baseline at 1 month post-treatment and further reduced at 3 months post-treatment, with a median reduction of 200.41 mg/g (IQR, 84.04-1057.10, P=0.028; percent change, 44.52% [IQR, 31.79%-65.42%]) (Figure 1a). No significant eGFR decline was observed through 3 months follow up(Figure 1b). sK+ levels remained within the range of 3.5-5.5 mmol/L with only minor fluctuations compared to baseline (Figure 1c). No treatment discontinuation or hospitalization due to hyperkalemia occurred.


Finerenone showed good effectiveness and safety in CKD without T2D patients in 3 month follow up. It should be verified by Future large prospective studies.